Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2012) 29 P1431

ICEECE2012 Poster Presentations Pituitary Clinical (183 abstracts)

Relationship between gsp mutations and clinico-pathological features in GH producing pituitary adenomas

K. Arita 1 , Y. Bakhtiar 1 , S. Yunoue 1 , M. Habu 1 , A. Tominaga 2 , H. Hirano 2 , J. Yasufuku-Takano 3 & K. Takano 3


1Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan; 2Graduate School of Biomedical Science, Hiroshima University, Hiroshima, Japan; 3Faculty of Medicine, University of Tokyo, Tokyo, Japan.


Purpose: To know the relationship between gsp mutations and clinico-pathological features in GH producing pituitary adenomas.

Subjects and methods: Somatotropinomas resected from 43 acromegalic patients, 18 males and 25 females, were examined for gsp mutation analysis. The mutation was detected in 25 of 43 (58.1%) tumours with alternations of Arg to Cys in codon 201 (68%), Arg to Ser in codon 201 (8%), Gln to Leu in codon 227 (20%) and Gln to Arg in codon 227 (4%).

Results: Incidence of gsp mutation tended to be higher in non-dot pattern (or densely granulated) adenomas (66.7%) than in dot in cytokeratin staining pattern (or sparsely granulated) adenomas (38.5%) (P=0.083). The tumour size was significantly smaller (P=0.006) and the GH-producing index was significantly larger (P=0.007) in adenoma with gsp mutations than those without gsp mutations. While all tumours with the mutation manifested an abnormal response to TRH challenge, this was the case in 50% of adenomae without gsp mutations (P=0.001). The ratio of abnormal response to LHRH also tended to be higher in adenoma with gsp mutations (P=0.095) We observed a good response to octreotide in 44.4% of adenoma with gsp mutations and in 18.2% of tumours without the mutation; the difference was not significant (P=0.217), possibly due to small sample size of cases who underwent octreotide test (n=20). The other clinico-pathological features (including age, sex, basal GH level and MIB-1 index) of the 43 patients were not significantly different, irrespective of their mutation status.

Conclusion: The existence of gsp mutation relates well to clinico-pathlogic features of growth hormone producing adenomas such as cytokeratin staining pattern, tumor size, and response to challenge test with TRH or LHRH.

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This work was supported, however funding details unavailable.

Volume 29

15th International & 14th European Congress of Endocrinology

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.